Results 151 to 160 of about 43,499 (244)

RAD21 Confers Poor Prognosis and Affects Ovarian Cancer Sensitivity to Poly(ADP-Ribose)Polymerase Inhibitors Through DNA Damage Repair. [PDF]

Front Oncol, 2022
Gou R, Li X, Dong H, Hu Y, Liu O, Liu J, Lin B.   +6 more
europepmc   +1 more source

Clinical Outcomes of Poly(ADP-Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of Korea. [PDF]

Curr Oncol
Ha HI, Yoon HJ, Song C, Kim ET, Suh DS, Kim KH, Na YJ, Song YJ.   +7 more
europepmc   +1 more source

Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis. [PDF]

Front Oncol, 2022
Luo J, Ou S, Wei H, Qin X, Jiang Q.
europepmc   +1 more source

Treatment Advances in Gynecologic Cancers: Insights From Recent Clinical Trials

Cancer Innovation, Volume 5, Issue 3, June 2026.
Overview of immunotherapy and antibody‐drug conjugates, and their mechanism against cancer. (The Graphical Abstract Image was created with BioRender.) ABSTRACT Gynecologic cancers remain a major global health burden for women. Their management has evolved toward a gynecologic oncologist‐led multimodal paradigm.
Yiyang Shen, Xiaofei Jiao, Yuanjia Wen, Zikun Peng, Xuejiao Zhao, Jiahao Liu, Qinglei Gao   +6 more
wiley   +1 more source

Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Combination with Chemotherapy for Advanced Breast Cancer: A Systematic Review and Meta-Analysis. [PDF]

Technol Cancer Res Treat
Duan Q, Feng Y, Cao L, Hu L, Wang J, Sun F, Meng Q, Zhou M, Yu J, Gao H.   +9 more
europepmc   +1 more source

Corrigendum: Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data. [PDF]

Front Pharmacol, 2022
Zhao Q, Ma P, Fu P, Wang J, Wang K, Chen L, Yang Y.   +6 more
europepmc   +1 more source

Enzymatic Synthesis of NAD+

Current Protocols, Volume 6, Issue 6, June 2026.
Abstract Nicotinamide adenine dinucleotide (NAD+) is an essential metabolite involved in numerous biological processes, functioning both as a redox cofactor in cellular energy metabolism and as a co‐substrate for NAD+‐utilizing enzymes, including sirtuins and poly(ADP‐ribose) polymerases.
Emily Boyle, Olivia Zhang, Yana Cen
wiley   +1 more source

Therapy-related myeloid neoplasms in Korean patients with ovarian or primary peritoneal cancer treated with poly(ADP-ribose) polymerase inhibitors. [PDF]

Transl Cancer Res
Jang YJ, Kim H, Ryu SY, Kim MH, Kim BJ, Jung HJ, Kang J, Yang SH, Na II, Lee HR, Kang HJ.   +10 more
europepmc   +1 more source

Homologous Recombination Repair Gene Variants and Outcomes Among Patients With Prostate Cancer Treated With Poly (ADP-ribose) Polymerase Inhibitors. [PDF]

JCO Precis Oncol, 2022
Price MJ, Vashistha V, Winski D, Kelley MJ, Bitting RL, Montgomery B.   +5 more
europepmc   +1 more source

Lysine lactylation‐mediated post‐translational modification: Molecular mechanisms and therapeutic target exploration in tumour drug resistance

Clinical and Translational Medicine, Volume 16, Issue 6, June 2026.
Lysine lactylation (Kla) serves as a metabolic–epigenetic switch governed by writer–eraser–reader regulatory systems, directly connecting the Warburg effect to diverse forms of tumour drug resistance. Intratumoural lactylation critically contributes to treatment failure in chemotherapy, targeted therapy and immunotherapy.
Juan Li, Yan Shang, Haojie Wu, Shenglong Yang, Maiqun Zuo, Hailong Zhao   +5 more
wiley   +1 more source